Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Post-Traumatic Headache Clinical Trial

Official title:

A Multidisciplinary Translational Approach to Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache - Human Studies Protocol: Individual Projects Excluding Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04369729
• Other study ID #: 20-003732
• Status: Recruiting
• Start date: September 9, 2020
• Est. completion date: August 2024

Study information

• Verified date: January 2024
• Source: Mayo Clinic
• Contact: Dani Smith
• Phone: 480-342-6524
• Email: Smith.Dani[@]mayo.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a United States Department of Defense funded Focused Program study that aims to identify mechanisms and predictors for persistent of post-traumatic headache attributed to mild traumatic brain injury, and identify methods of preventing post-traumatic headache persistence

Description:

The human studies component of this Focused Program include clinical phenotyping, neurophysiology, molecular and genetic biomarker discovery, and brain imaging. This data will be utilized to characterize post-traumatic headache and build univariate and multivariate predictive models for post-traumatic headache persistence and for the response to post-traumatic headache treatment. Some participants might be eligible to participate in the clinical trial portion of this study.The clinical trial is a double-blind, randomized, placebo-controlled investigation of erenumab for the treatment of post-traumatic headache. Participants will be randomized when PTH has been present for 35-56 days. The clinical trial component of this Focused Program is described in more detail in a separate clinicaltrials.gov record. Follow-up questionnaires, headache diary data, pain threshold results, and brain imaging data will be collected longitudinally during the trial to assess for changes over time and associations of such changes with post-traumatic headache treatment outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 264
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

POST-TRAUMATIC HEADACHE ELIGIBILITY CRITERIA

Inclusion Criteria:

• Have a diagnosis of acute PTH attributed to mild traumatic injury to the head as defined by the International Classification of Headache Disorders (ICHD-3).
• PTH onset 7-56 days prior to the time of enrollment.
• Adults 18-70 years of age.
• Willing to maintain a headache diary.
• Willing and able to return for follow-up visits.

Exclusion Criteria:

• Chronic headache (i.e. at least 15 headache days/month for more than 3 months) within 12 months prior to the mTBI that led to the current PTH, including PPTH, chronic migraine, medication overuse headache, new daily persistent headache, hemicrania continua, chronic tension-type headache.
• Diminished decision-making capacity that in the investigator's opinion would interfere with the person's ability to provide informed consent and complete study procedures.
• Started or changed dose of a headache preventive medication within the 3 months prior to screening.
• Use of onabotulinumtoxinA in the head, neck or face region within 6 months of screening.
• During the 6 months before screening, use of opioids or barbiturates on at least 4 days per month.
• Subjects who underwent an intervention or used a device (e.g., nerve blocks, transcranial magnetic stimulation, vagal nerve stimulation, or electrical trigeminal nerve stimulation) for headache.
• History of major psychiatric disorder such as schizophrenia and bipolar disorder.
• History or evidence of any unstable or clinically significant medical condition, that in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
• History of positive neuroimaging findings that indicate a moderate or severe TBI.
• Contraindications to magnetic resonance imaging, including, but not limited to (only

for those individuals participating in the MRI portion of this research):

1. Metal implants

2. Aneurysm clips

3. Severe claustrophobia

4. Implanted electronic devices

5. Insulin or infusion pump

6. Cochlear/otologic/ear implant

7. Non-removable prosthesis

8. Implanted shunts/catheters

9. Certain intrauterine devices

10. Tattooed makeup

11. Body piercings that cannot be removed

12. Metal fragments

13. Wire sutures or metal staples

• Factors that reduce MR image quality and interpretability (only for those individuals

participating in the MRI portion of this research):

1. Dental braces or other non-removable devices (e.g., retainers)

2. Prior brain surgery

3. Known brain MRI abnormality that in the investigator's opinion will significantly impact MRI data.

• Sensory disorders that in the investigator's opinion might affect perception of cutaneous thermal stimuli (e.g., peripheral neuropathy) (only for those individuals undergoing pain threshold testing).
• Pregnancy
• Breastfeeding
• Currently or within 90 days prior to screening: received treatment in another drug study or an investigational device study. HEALTHY CONTROL ELIGIBILITY CRITERIA

Inclusion Criteria:

• Adults 18-70 years of age.
• Willing and able to return for follow-up visits.

Exclusion Criteria:

• History of traumatic brain injury.
• History of migraine or other headaches (Tension-type headache up to an average of 3 days per month is allowed).
• Diminished decision-making capacity that in the investigator's opinion would interfere with the person's ability to provide informed consent and complete study procedures.
• During the 6 months before screening, use of opioids or barbiturates on an average of at least 4 days per month.
• History of major psychiatric disorder such as schizophrenia and bipolar disorder.
• History or evidence of any unstable or clinically significant medical condition, that in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
• Contraindications to magnetic resonance imaging, including, but not limited to:

1. Metal implants

2. Aneurysm clips

3. Severe claustrophobia

4. Implanted electronic devices

5. Insulin or infusion pump

6. Cochlear/otologic/ear implant

7. Non-removable prosthesis

8. Implanted shunts/catheters

9. Certain intrauterine devices

10. Tattooed makeup

11. Body piercings that cannot be removed

12. Metal fragments

13. Wire sutures or metal staples

• Factors that reduce MR image quality and interpretability:

1. Dental braces or other non-removable devices (e.g., retainers)

2. Prior brain surgery

3. Known brain MRI abnormality that in the investigator's opinion will significantly impact MRI data.

• Sensory disorders that in the investigator's opinion might affect perception of cutaneous thermal stimuli (e.g., peripheral neuropathy).
• Pregnancy
• Breastfeeding
• Currently or within 90 days prior to screening: received treatment in another drug study or an investigational device study
• Has previously received any CGRP ligand or receptor targeted monoclonal antibody

Related Conditions & MeSH terms

• Headache
• Post-Traumatic Headache

Locations

Country	Name	City	State
United States	Mayo Clinic	Jacksonville	Florida
United States	Mayo Clinic	Phoenix	Arizona
United States	Phoenix VA Health Care System	Phoenix	Arizona
United States	Mayo Clinic	Rochester	Minnesota
United States	Mayo Clinic	Scottsdale	Arizona

Sponsors (7)

Lead Sponsor	Collaborator
Mayo Clinic	Amgen, Arizona State University, Phoenix VA Health Care System, Translational Genomics Research Institute, United States Department of Defense, University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Longitudinal Assessment of PTH Phenotype	descriptive analysis of post-traumatic headache characteristics such as headache frequency and severity, and characteristics of associated conditions such as symptoms of sensory hypersensitivities, anxiety, depression, insomnia, autonomic dysfunction, and cognitive function	baseline with longitudinal follow-up at weeks four and sixteen
Primary	Longitudinal Assessment of Cutaneous Pain Thresholds	heat pain thresholds on the skin determined by quantitative sensory testing	baseline with longitudinal follow-up at weeks four and sixteen
Primary	Longitudinal Assessment of Visual Pain Thresholds from Bright Light Exposure	visual pain thresholds to different light intensities	baseline with longitudinal follow-up at weeks four and sixteen
Primary	Longitudinal Assessment of Brain MRI	structural brain imaging to include measures such as cortical thickness, regional volumes, brain curvature, white matter tract integrity, and functional brain imaging measures such as resting state functional connectivity and pain-induced brain activation	baseline with longitudinal follow-up at weeks four and sixteen
Primary	Longitudinal Assessment of Blood Based Biomarkers	blood-based biomarkers, including DNA and targeted serum proteins, associated with acute and persistent post-traumatic headache and response to therapy	baseline with longitudinal follow-up at weeks four and sixteen
Primary	Longitudinal Assessment of Post-traumatic Headache Biomarkers	clinical characteristics, pain thresholds, and brain imaging features as described above that are associated with acute post-traumatic headache and persistent post-traumatic headache; that predict the persistent of post-traumatic headache; and that predict and measure treatment response	baseline with longitudinal follow-up at weeks four and sixteen

External Links

•   Mayo Clinic Clinical Trials